Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 402 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: PAH Clear all
Completed No phase listed Observational

OPsumit USers Registry

NCT02126943
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Opsumit (macitentan)
Drug
Lead sponsor
Actelion
Industry
Eligibility
Not listed
Enrollment
2,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
144
States / cities
Mobile, Alabama • Phoenix, Arizona • Fullerton, California + 117 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 2:51 PM EDT
Terminated Phase 3 Interventional Results available

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

NCT00723554
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Iloprost PD-6, Iloprost PD-15
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 23, 2026, 2:51 PM EDT
Active, not recruiting Not applicable Interventional

Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)

NCT03288025
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Insulin Resistance
Interventions
Nutrition and Exercise
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 2:51 PM EDT
Recruiting Not applicable Interventional

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)

NCT03138863
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
Interventions
BALT GoldbBAL2 Detachable Balloon, Catheter System
Device
Lead sponsor
Rodrigo Ruano
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 2:51 PM EDT
Completed No phase listed Observational Results available

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

NCT03888365
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil, Non-Treprostinil PAH Medications
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Timeline
2019
U.S. locations
10
States / cities
Birmingham, Alabama • Beverly Hills, California • Santa Barbara, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

NCT00549302
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 23, 2026, 2:51 PM EDT
Terminated Phase 4 Interventional Results available

Crossover Study From Macitentan or Bosentan Over to Ambrisentan

NCT02885012
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
New Orleans, Louisiana • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 23, 2026, 2:51 PM EDT
Terminated Phase 1 Interventional

Carvedilol PAH A Pilot Study of Efficacy and Safety

NCT02120339
View directory record Official record
Conditions
Pulmonary Hypertension, Cardiac MRI <40
Interventions
Carvedilol
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Benzo[a]Pyrene Ultralow Dose-Response Study

NCT03318978
View directory record Official record
Conditions
Environmental Exposure
Interventions
[14C]-benzo[a]pyrene
Drug
Lead sponsor
Oregon State University
Other
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 23, 2026, 2:51 PM EDT
Completed No phase listed Observational

Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension

NCT05521113
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Home Rehabilitation Monitoring System, Health coaching calls
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

NCT00159913
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Children
Interventions
Sildenafil citrate, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
10
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT05147805
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

NCT03528902
View directory record Official record
Conditions
Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
Interventions
Tamoxifen, Placebo Oral Tablet
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

NCT02279160
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
APD811, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 23, 2026, 2:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

NCT07143448
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
HS235, Placebo
Biological · Other
Lead sponsor
35Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 2:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Placental and Cord Blood Markers Associated With Premature Birth and Disorders of Premature Birth in Newborn Infants

NCT01439048
View directory record Official record
Conditions
Premature Birth
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Minute to 3 Months
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

FUTURE 3 Study Extension

NCT01338415
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Bosentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
3 Months to 12 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 2:51 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

PET Image in PAH Patients

NCT05452889
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
18F-FGLN PET Imaging, (18F)FPGLU
Diagnostic Test · Drug
Lead sponsor
Stephen Y. Chan
Other
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 2:51 PM EDT
Completed No phase listed Observational

A Registry for Patients Taking Uptravi

NCT03278002
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01178073
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
ambrisentan, tadalafil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

NCT01757808
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 72 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional

Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension

NCT00004497
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
8 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
7
States / cities
Torrance, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00792571
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium Modified Release
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Torrance, California • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 23, 2026, 2:51 PM EDT